Quality-of-Life in Melanoma Patients treated with Immunotherapy: a Qualitop Cohort Study

5% progressed in the liver first.Those with extrahepatic before intrahepatic progression had longer OS from treatment start than those with simultaneous progression (median 19.6 vs. 6.8 months; p=0.015). Clinical featureHazard ratio (95% Confidence Interval) LDH > ULN 1.29 (0.81-2.08)Neutrophils > median 1.50 (0.97-2.30)Lymphocytes < median 1.12 (0.73-1.72)NLR > median 1.40 (0.91-2.16)AST > ULN 1.82 (1.13-2.94)ALP > ULN 2.16 (1.33-3.51)Albumin < median 2.28 (1.43-3.64)Bilirubin > median 1.15 (0.74-1.77)Sodium < median 1.74 (1.11-2.74)Estimated hazard ratios.Total cohort: n = 163 Conclusions: Markers of hepatic impairment were associated with poorer prognosis among pts with melanoma liver metastasis.Pts with extrahepatic before intrahepatic progression had longer OS.Crude response rates were lowest for liver with bone metastases compared to other disease site combinations.

Authors

Institutions

Publication Details

Journal
EJC Skin Cancer
Published
2025-01-01
DOI
https://doi.org/10.1016/j.ejcskn.2025.100556
Primary Topic
Cutaneous Melanoma Detection and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quality-of-Life in Melanoma Patients treated with Immunotherapy: a Qualitop Cohort Study

S. Podlipnik, Pablo A. Iglesias, Concepción Blanco Carrera, M. Luque‐Luna et al.
EJC Skin Cancer
Cutaneous Melanoma Detection and Management
article

Quality-of-Life in Melanoma Patients treated with Immunotherapy: a Qualitop Cohort Study

S. Podlipnik, Pablo A. Iglesias, Concepción Blanco Carrera, M. Luque‐Luna, J. Malvehy, A. Fournier, S. Dalle, Delphine Maucort‐Boulch, Etienne Coz, Susana Puig, F. Crespí-Payeras, M. Gracia-Rius
article en

Abstract

5% progressed in the liver first.Those with extrahepatic before intrahepatic progression had longer OS from treatment start than those with simultaneous progression (median 19.6 vs. 6.8 months; p=0.015). Clinical featureHazard ratio (95% Confidence Interval) LDH > ULN 1.29 (0.81-2.08)Neutrophils > median 1.50 (0.97-2.30)Lymphocytes < median 1.12 (0.73-1.72)NLR > median 1.40 (0.91-2.16)AST > ULN 1.82 (1.13-2.94)ALP > ULN 2.16 (1.33-3.51)Albumin < median 2.28 (1.43-3.64)Bilirubin > median 1.15 (0.74-1.77)Sodium < median 1.74 (1.11-2.74)Estimated hazard ratios.Total cohort: n = 163 Conclusions: Markers of hepatic impairment were associated with poorer prognosis among pts with melanoma liver metastasis.Pts with extrahepatic before intrahepatic progression had longer OS.Crude response rates were lowest for liver with bone metastases compared to other disease site combinations.

EJC Skin CancerVol. 3
Université Claude Bernard Lyon 1 (FR), Centre National de la Recherche Scientifique (FR), Instituto de Salud Carlos III (ES), Hospices Civils de Lyon (FR), Centre for Biomedical Network Research on Rare Diseases (ES), Hospital Clínic de Barcelona (ES), Centre de Recherche en Cancérologie de Lyon (FR), Laboratoire de Biométrie et Biologie Evolutive (FR), Fundació Clínic per a la Recerca Biomèdica (ES), Instituto de Investigación de Enfermedades Raras (ES), Universitat de Barcelona (ES)
Zero hunger
Openalex Percentile: Top 90%
Cutaneous Melanoma Detection and Management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.